297 related articles for article (PubMed ID: 11493332)
1. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis.
Ohshima K; Kawasaki C; Muta H; Muta K; Deyev V; Haraoka S; Suzumiya J; Podack ER; Kikuchi M
Histopathology; 2001 Aug; 39(2):156-62. PubMed ID: 11493332
[TBL] [Abstract][Full Text] [Related]
2. Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression.
Kuo SH; Chen LT; Wu MS; Kuo KT; Yeh KH; Doong SL; Yeh PY; Hsu HC; Tzeng YS; Lin CW; Lin JT; Cheng AL
J Pathol; 2007 Feb; 211(3):296-304. PubMed ID: 17167822
[TBL] [Abstract][Full Text] [Related]
3. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma.
Fang JM; Finn WG; Hussong JW; Goolsby CL; Cubbon AR; Variakojis D
Mod Pathol; 1999 Mar; 12(3):295-300. PubMed ID: 10102615
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of bcl-6 protein expression and gene rearrangement in diffuse large B-cell lymphoma].
Min DL; Xia HL; Zhou XY; Sun MH; Yang WT; Zhang TM; Zheng AH; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):327-31. PubMed ID: 16185497
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of CD10 and t(14;18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B-cell lymphoma.
McCluggage WG; Catherwood M; Alexander HD; McBride HA; Smith ME; Morris TC
Histopathology; 2002 Nov; 41(5):414-20. PubMed ID: 12405909
[TBL] [Abstract][Full Text] [Related]
6. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma.
Ye H; Dogan A; Karran L; Willis TG; Chen L; Wlodarska I; Dyer MJ; Isaacson PG; Du MQ
Am J Pathol; 2000 Oct; 157(4):1147-54. PubMed ID: 11021819
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma.
Uherova P; Ross CW; Schnitzer B; Singleton TP; Finn WG
Am J Clin Pathol; 2001 Apr; 115(4):582-8. PubMed ID: 11293907
[TBL] [Abstract][Full Text] [Related]
8. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.
Biasoli I; Morais JC; Scheliga A; Milito CB; Romano S; Land M; Pulcheri W; Spector N
Histopathology; 2005 Mar; 46(3):328-33. PubMed ID: 15720419
[TBL] [Abstract][Full Text] [Related]
9. Infrequent BCL10 mutations in B-cell non-Hodgkin's lymphomas.
Takahashi H; Hosokawa Y; Suzuki R; Morishima Y; Nakamura S; Seto M
Jpn J Cancer Res; 1999 Dec; 90(12):1316-20. PubMed ID: 10665648
[TBL] [Abstract][Full Text] [Related]
10. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas.
Dogan A; Bagdi E; Munson P; Isaacson PG
Am J Surg Pathol; 2000 Jun; 24(6):846-52. PubMed ID: 10843287
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
13. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
14. Bcl10 expression, rearrangement and mutation in MALT lymphoma: correlation with expression of nuclear factor-kappaB.
Ohshima K; Muta H; Kawasaki C; Muta K; Deyev V; Kanda M; Kumano Y; Podack ER; Kikuchi M
Int J Oncol; 2001 Aug; 19(2):283-9. PubMed ID: 11445840
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma].
Yin HF; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 39(2):158-62. PubMed ID: 17440591
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy.
Veelken H; Vik Dannheim S; Schulte Moenting J; Martens UM; Finke J; Schmitt-Graeff A
Ann Oncol; 2007 May; 18(5):931-9. PubMed ID: 17395602
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.
Anderson JJ; Fordham S; Overman L; Dignum H; Wood K; Proctor SJ; Crosier S; Angus B; Culpin RE; Mainou-Fowler T
Int J Oncol; 2009 Nov; 35(5):961-71. PubMed ID: 19787248
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
20. Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor.
Oh YH; Park CK
J Korean Med Sci; 2006 Jun; 21(3):397-405. PubMed ID: 16778379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
